Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C15H17N3O.ClH |
| Molecular Weight | 291.776 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.COC1=CC2=C(C=C1)N3CCN(C)C4=NCCC2=C34
InChI
InChIKey=RQQVSZWEVNAKGW-UHFFFAOYSA-N
InChI=1S/C15H17N3O.ClH/c1-17-7-8-18-13-4-3-10(19-2)9-12(13)11-5-6-16-15(17)14(11)18;/h3-4,9H,5-8H2,1-2H3;1H
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C15H17N3O |
| Molecular Weight | 255.315 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Metralindole (Inkazan) is a reversible inhibitor of monoamine oxidase A (RIMA) which was used in Russia as an antidepressant. Inkasan (3-methyl-8-methoxy-3H, 1,2,5,6- tetrahydropyrazine /1.2.3-ab/-beta-carboline hydrochloride) has pharmacological properties characteristic of antidepressants. The clinical antidepressant effect of inkasan is combined with stimulating action. The drug is primarily indicated for patients in whom adynamic (anergic) disturbances are predominant in the clinical picture of depression.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL3358 |
|||
Target ID: CHEMBL3358 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Inkazan Approved UseTreatment of depression. The drug is primarily indicated for patients in whom adynamic (anergic) disturbances are predominant in the clinical picture of depression. |
Sample Use Guides
In Vivo Use Guide
Curator's Comment: Metralindole (Inkazan) was also used orally (10 mg/kg)
https://www.ncbi.nlm.nih.gov/pubmed/2728714
Cats: Electroencephalographic investigations conducted by L. F. Roshchina showed that in cats
inkazan in doses of 10-40 mg/kg (intravenously) caused increased cortical and subcortical
activity and intensified the reaction of cortex to photo- and photon stimulation. The electrophysiological
response of inkazan persists for 3-4 h. In doses of 5-50 mg/kg administered
intraperitoneally, the preparation slows conditioned reflexes of avoidance in rats.
Route of Administration:
Other
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 03:46:39 UTC 2023
by
admin
on
Sat Dec 16 03:46:39 UTC 2023
|
| Record UNII |
M15TM76Y3L
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID90202016
Created by
admin on Sat Dec 16 03:46:39 UTC 2023 , Edited by admin on Sat Dec 16 03:46:39 UTC 2023
|
PRIMARY | |||
|
M15TM76Y3L
Created by
admin on Sat Dec 16 03:46:39 UTC 2023 , Edited by admin on Sat Dec 16 03:46:39 UTC 2023
|
PRIMARY | |||
|
DBSALT001789
Created by
admin on Sat Dec 16 03:46:39 UTC 2023 , Edited by admin on Sat Dec 16 03:46:39 UTC 2023
|
PRIMARY | |||
|
53734-79-5
Created by
admin on Sat Dec 16 03:46:39 UTC 2023 , Edited by admin on Sat Dec 16 03:46:39 UTC 2023
|
PRIMARY | |||
|
171296
Created by
admin on Sat Dec 16 03:46:39 UTC 2023 , Edited by admin on Sat Dec 16 03:46:39 UTC 2023
|
PRIMARY | |||
|
m7501
Created by
admin on Sat Dec 16 03:46:39 UTC 2023 , Edited by admin on Sat Dec 16 03:46:39 UTC 2023
|
PRIMARY | Merck Index |